Corindus Partners with Houston Methodist DeBakey Heart & Vascular Center

12/3/17

WALTHAM, Mass.--(BUSINESS WIRE)--Corindus Vascular Robotics, Inc. (NYSE American: CVRS), a leading developer of precision vascular robotics, announced today that Houston Methodist DeBakey Heart & Vascular Center, a leading cardiovascular center located in the Texas Medical Center, has launched the first vascular robotic program in the Houston area with the installation of two CorPath® GRX Systems. In addition and as part of the program launch, Corindus will partner with Houston Methodist to develop a Global Center of Excellence that will seek to advance clinical research on robotics and to train interventional cardiologists on robotic-assisted percutaneous coronary interventions (PCI).

Recently named the No. 1 hospital in Texas for the sixth year in a row by U.S. News & World Report, Houston Methodist Hospital brings together cardiologists, cardiovascular surgeons and cardiovascular anesthesiologists who take a collaborative approach to patient care and research. The hospital, which performs 1,100 PCIs annually, is adopting robotics to improve precision and enhance safety for cath lab professionals.

Mark Toland, President and Chief Executive Officer of Corindus, stated, "Houston Methodist is a world-class center and the ideal partner to educate the interventional community on current applications of robotics. The hospital’s leadership and innovation in cardiovascular medicine will help us to advance the field of vascular robotics."

The Houston Methodist Institute for Technology, Innovation & Education (MITIESM), an innovative virtual hospital and hands-on clinical training facility, will be a robotic-assisted PCI training center. Physicians attending courses at Houston Methodist will participate in didactic education, live case observation with a trained robotic interventionalist, and a unique workshop for a hands-on introduction to robotic-assisted PCI.

Alan Lumsden, M.D., Chief of the Department of Cardiovascular Surgery at Houston Methodist, stated, "We pride ourselves on leading the way in embracing innovative technologies that improve patient care. With adoption of robotics in the cath lab on the rise, comprehensive training programs and innovative product developments are key factors for success."

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc. is a global technology leader in robotic-assisted vascular interventions. The company's CorPath® System is the first FDA-cleared medical device to bring robotic precision to percutaneous coronary interventions. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures. Corindus stands behind its product with its unique $1,000 hospital credit "One Stent Program." For additional information, visit www.corindus.com, and follow @CorindusInc.

About Houston Methodist DeBakey Heart & Vascular Center

Patients from around the world choose Houston Methodist DeBakey Heart & Vascular Center for access to state-of-the-art resources at Houston Methodist Hospital in the Texas Medical Center. The center is staffed by more than 125 heart specialists and 1,000 employees, and boasts 10 operating rooms, 9 catheterization labs, 176 acute-care beds, 58 ICU beds and 43 transplant beds. The center has more than 100 clinical trials currently underway. The Center is ranked No. 21 by U.S. News & World Report among the 694 best hospitals in the United States for cardiology and heart surgery.

Recent Deals

Interested in advertising your deals? Contact Edwin Warfield.